Fachthema

Refractory non-Hodgkin lymphoma

Responses to CAR T-cell therapy still strong after one year

Jatros Digital, 28.11.2017
Hämatologie | Onkologie

Sattva S. Neelapu, MD, The University of Texas MD Anderson Cancer Center, presents the long-term follow-up of ZUMA-1: a pivotal trial of axicabtagene ciloleucel (axi-cel; KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma (NHL).

zurück zum ASH Newsroom 2017